Skip to content

To Evaluate the Safety and Effectiveness of Intrauterine Adhesion Preventer in the Prevention and Treatment of Intrauterine Adhesions, a Prospective, Multicenter, Randomized Controlled Clinical Trial

To Evaluate the Safety and Effectiveness of Intrauterine Adhesion Preventer in the Prevention and Treatment of Intrauterine Adhesions, a Prospective, Multicenter, Randomized Controlled Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07611474
Enrollment
200
Registered
2026-05-28
Start date
2021-01-01
Completion date
2031-12-31
Last updated
2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine Adhesion, Intrauterine Adhesions

Brief summary

To evaluate the effect of uterine stents in preventing intrauterine adhesions after intrauterine operation and whether they meet the safety requirements for clinical use. The trial adopted a prospective, multicenter, randomized controlled, non-inferiority clinical trial design. The target population of the trial was 200 women aged 20-40 years with intrauterine adhesions and surgical indications (referring to those with fertility requirements or menstrual blood drainage obstruction), who were randomly divided into an experimental group and a control group, with 100 cases in each group. The experimental group was the group with intrauterine stents placed in the uterine cavity after hysteroscopic intrauterine adhesion separation surgery, and the control group was the group with intrauterine rings + balloons + sodium hyaluronate gel placed in the uterine cavity. After 3 courses of artificial cycles, the patients were hospitalized for hysteroscopy review.

Interventions

DEVICEUterine stent group

After TCRA, uterine stents of different specifications were placed in the uterine cavity according to the different uterine cavity morphologies of the subjects, and the hysteroscope was inserted again to adjust the position of the uterine stent.

DEVICEUterine ring + balloon + sodium hyaluronate gel

The subjects were hospitalized for TCRA surgery. After the surgery, different types of uterine rings were selected and inserted into the uterine cavity according to the morphology of the subjects' uterine cavity. At the same time, a No. 12 Foley catheter was left in the uterine cavity, and 2.5 ml of normal saline was injected into the catheter balloon. 2 ml of hyaluronic acid gel was injected into the uterine cavity on one side of the catheter. The doctor removed the Foley catheter on the first day after the surgery.

Sponsors

The Third Xiangya Hospital of Central South University
Lead SponsorOTHER
Hunan Haokang Medical Technology Co., Ltd.
CollaboratorUNKNOWN
Beijing Tiantan Hospital
CollaboratorOTHER
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Patients clinically diagnosed with intrauterine adhesions and with surgical indications (referring to those with fertility requirements or obstructed menstrual blood drainage) ② Women aged 20-40 years old; ③ Subjects voluntarily participated in the trial and signed informed consent.

Exclusion criteria

* ① Patients with obviously abnormal uterine cavity shape after surgery; those who could not clearly separate the normal uterine cavity anatomical morphology (i.e. bilateral or unilateral fallopian tube openings were not visible); those with reproductive organ malformations and uterine cavities that were too large or too small; those with recent uterine perforation; those with cervical insufficiency. * Those with a history of intrauterine adhesions and treatment; * Those with endometrial tuberculosis or suspected endometrial tuberculosis; * Those with adenomyosis or uterine fibroids\>4cm; * Those with a history of malignant tumors or suspected malignant tumors; * Those with acute and chronic intrauterine infection and genital infection; * Those with unexplained vaginal bleeding or suspected uterine malignant lesions; * Those with severe anemia and abnormal coagulation function; those with a history of thrombosis; ⑨ Those in the acute stage of various diseases or severe systemic diseases; * Those with severe mental illness and physical weakness who cannot tolerate this operation; ⑪ Those with severe heart, liver, and kidney function diseases; ⑫ Those with contraindications to anesthesia or surgery; ⑬ Those who have participated in clinical trials in the past three months. * Those who are considered unsuitable for inclusion by the researchers.

Design outcomes

Primary

MeasureTime frameDescription
Intrauterine adhesion rateAt 12 months after the index hysterectomyRefer to the 2017 American Fertility Association IUA guidelines AFS score. AFS score: The case with adhesion whose total AFS score decreased by ≥ 4 points was considered effective. The effective rate was calculated using the following formula: number of cases with total AFS score decreased by ≥ 4 points/total number of cases × 100%.

Countries

China

Contacts

CONTACTDabao MD
forxudabao@126.com13017386201

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 29, 2026